VectorY Therapeutics announced a €74.5 million ($83.5 million) Series A funding round aimed at antibody gene therapies for neurodegenerative diseases. The company’s lead program, VTx-002, is designed to generate therapeutic antibodies in the brain, and the capital will fund continued development toward clinical milestones. For investors and pipeline planners, the financing is a signal of continued risk appetite for neurology gene therapy platforms that differentiate on route of administration and expression control. It also underscores the market pull for programs that attempt to address CNS pathology with intracellular or in situ biologic generation. Details on specific trial phases were not included in the provided text, but the stated therapeutic focus suggests near-term activity will center on vector optimization, preclinical-to-clinical translation, and early safety/biomarker readouts.